ContraFect Corp.
(NASDAQ : CFRX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 10.73%61.500.0%$1907.60m
REGNRegeneron Pharmaceuticals, Inc. 5.98%612.812.5%$1175.40m
GILDGilead Sciences, Inc. 3.33%77.831.0%$1168.63m
AMGNAmgen, Inc. 2.49%229.701.3%$672.54m
VRTXVertex Pharmaceuticals, Inc. 3.81%287.961.9%$606.67m
NVAXNovavax, Inc. 2.68%46.04102.0%$590.02m
BIIBBiogen, Inc. 2.19%307.091.6%$417.42m
ILMNIllumina, Inc. -2.67%363.053.5%$387.48m
SRNESorrento Therapeutics, Inc. 2.02%5.051.8%$306.68m
ALXNAlexion Pharmaceuticals, Inc. 4.79%119.902.0%$292.13m
SGENSeattle Genetics, Inc. 3.74%157.216.1%$269.08m
AAgilent Technologies, Inc. 1.67%88.141.6%$202.48m
BMRNBioMarin Pharmaceutical, Inc. 0.90%106.554.3%$186.35m
CODXCo-Diagnostics, Inc. 3.03%18.000.0%$173.36m
INCYIncyte Corp. 1.35%101.912.5%$166.15m

Company Profile

ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.